Alpha Glucosidase Inhibitors
SKU
MRR-456C7E866918
Region
Global
Publication Date
February 2024
Delivery
Immediate
2023
USD 616.76 million
2030
USD 1,591.49 million
2024
USD 703.76 million
CAGR
14.50%
Alpha Glucosidase Inhibitors Market by Drug class (Acarbose (Precose), Miglitol (Glyset), Voglibose), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2024-2030

[182 Pages Report] The Alpha Glucosidase Inhibitors Market size was estimated at USD 616.76 million in 2023 and expected to reach USD 703.76 million in 2024, at a CAGR 14.50% to reach USD 1,591.49 million by 2030.

Alpha Glucosidase Inhibitors Market
To learn more about this report, request a free sample copy
Alpha-glucosidase inhibitors (AGIs) are a class of oral anti-diabetic medications that delay the absorption of carbohydrates from the digestive tract, thereby decreasing the rise in blood glucose levels after a meal. They act by inhibiting the enzyme alpha-glucosidase in the intestinal wall, which is responsible for the breakdown of carbohydrates into glucose. The primary driver is the increasing prevalence of type 2 diabetes globally, coupled with the growing awareness of diabetes management. The efficacy of AGIs in controlling postprandial glucose levels makes them a favorable adjunct therapy. However, the restraints, such as gastrointestinal side effects associated with AGIs, can limit patient compliance. The availability of alternative therapies and generics also restricts its adoption. Challenges include stringent regulatory scenarios that make drug approval processes longer and more expensive. Additional challenges lie in the need for clinical differentiation from other antidiabetics and the management of complex drug-drug interactions. Opportunities include the development of next-generation drugs with fewer side effects. There's also potential in emerging markets with increasing diabetic populations that are currently underserved. Research into combination therapies and personalized medicine may lead to broader applications.
Alpha Glucosidase Inhibitors Market - Global Forecast 2024-2030
To learn more about this report, request a free sample copy
FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alpha Glucosidase Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alpha Glucosidase Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alpha Glucosidase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Avecia Healthcare, Bal Pharma Ltd., Bayer AG, Biocon, BioVision Inc. by Abcam US Group Holdings Inc., Cipla Ltd., Elder Pharmaceuticals Ltd., Empros Pharma AB, Glenmark Pharmaceuticals Ltd., Lunan Pharmaceuticals Group, Manus Aktteva Biopharma LLP, Merck KGaA, Micro Labs Ltd., Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd., Novo Nordisk A/S, Samex Overseas, Sanofi S.A., Shenzhen Haorui Pharmatech Co., Ltd., Straight Healthcare, Strides Arcolab Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Torrent Pharmaceuticals Ltd., and Wockhardt Ltd..

Market Segmentation & Coverage

This research report categorizes the Alpha Glucosidase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug class
    • Acarbose (Precose)
    • Miglitol (Glyset)
    • Voglibose
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End-Users
    • Home Healthcare
    • Hospitals & Clinics
    • Specialty Diabetes Centers

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Alpha Glucosidase Inhibitors Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alpha Glucosidase Inhibitors Market?
  3. What are the technology trends and regulatory frameworks in the Alpha Glucosidase Inhibitors Market?
  4. What is the market share of the leading vendors in the Alpha Glucosidase Inhibitors Market?
  5. Which modes and strategic moves are suitable for entering the Alpha Glucosidase Inhibitors Market?

  1. Preface
    1. Objectives of the Study
    2. Market Segmentation & CoverageALPHA GLUCOSIDASE INHIBITORS MARKET SEGMENTATION & COVERAGE
    3. Years Considered for the Study
    4. Currency & PricingUNITED STATES DOLLAR EXCHANGE RATE, 2018–2023
    5. Language
    6. Limitations
    7. Assumptions
    8. Stakeholders
  2. Research Methodology
    1. ALPHA GLUCOSIDASE INHIBITORS MARKET RESEARCH PROCESS
    2. Define: Research Objective
    3. Determine: Research Design
    4. Prepare: Research Instrument
    5. Collect: Data Source
    6. Analyze: Data Interpretation
    7. Formulate: Data Verification
    8. Publish: Research Report
    9. Repeat: Report Update
  3. Executive Summary
    1. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2023 VS 2030
  4. Market Overview
    1. IntroductionALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
    2. Alpha Glucosidase Inhibitors Market, by RegionALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  5. Market Insights
    1. Market DynamicsALPHA GLUCOSIDASE INHIBITORS MARKET DYNAMICS
      1. Drivers
        1. Prevalence of type 2 diabetes and need for improved care
        2. Government initiatives and policies encouraging diabetes management
        3. Increasing focus on combination therapies with alpha-glucosidase inhibitors
      2. Restraints
        1. Difficulties of API approval and dosing regimen
      3. Opportunities
        1. Ongoing R&D activities for new alpha-glucosidase inhibitor discovery
        2. Personalized medicine approaches for improved alpha-glucosidase inhibitor efficacy
      4. Challenges
        1. Concerns associated with gastrointestinal side effects and drug interactions
    2. Market Segmentation Analysis
    3. Market Trend Analysis
    4. Cumulative Impact of High Inflation
    5. Porter’s Five Forces Analysis
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Customers
      4. Bargaining Power of Suppliers
      5. Industry Rivalry
    6. Value Chain & Critical Path Analysis
    7. Regulatory Framework
  6. Alpha Glucosidase Inhibitors Market, by Drug class
    1. IntroductionALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
    2. Acarbose (Precose)ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ACARBOSE (PRECOSE), BY , 2018-2030 (USD MILLION)
    3. Miglitol (Glyset)ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MIGLITOL (GLYSET), BY , 2018-2030 (USD MILLION)
    4. VogliboseALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY VOGLIBOSE, BY , 2018-2030 (USD MILLION)
  7. Alpha Glucosidase Inhibitors Market, by Distribution Channel
    1. IntroductionALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    2. Hospital PharmaciesALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY , 2018-2030 (USD MILLION)
    3. Online PharmaciesALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY , 2018-2030 (USD MILLION)
    4. Retail PharmaciesALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY , 2018-2030 (USD MILLION)
  8. Alpha Glucosidase Inhibitors Market, by End-Users
    1. IntroductionALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    2. Home HealthcareALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOME HEALTHCARE, BY , 2018-2030 (USD MILLION)
    3. Hospitals & ClinicsALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOSPITALS & CLINICS, BY , 2018-2030 (USD MILLION)
    4. Specialty Diabetes CentersALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY SPECIALTY DIABETES CENTERS, BY , 2018-2030 (USD MILLION)
  9. Americas Alpha Glucosidase Inhibitors Market
    1. Introduction
    2. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    3. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Argentina
    5. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    6. Brazil
    7. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    8. Canada
    9. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    10. Mexico
    11. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    12. United States
    13. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    14. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  10. Asia-Pacific Alpha Glucosidase Inhibitors Market
    1. Introduction
    2. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    3. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Australia
    5. AUSTRALIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)AUSTRALIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)AUSTRALIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    6. China
    7. CHINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)CHINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)CHINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    8. India
    9. INDIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)INDIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)INDIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    10. Indonesia
    11. INDONESIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)INDONESIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)INDONESIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    12. Japan
    13. JAPAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)JAPAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)JAPAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    14. Malaysia
    15. MALAYSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)MALAYSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)MALAYSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    16. Philippines
    17. PHILIPPINES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)PHILIPPINES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)PHILIPPINES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    18. Singapore
    19. SINGAPORE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SINGAPORE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)SINGAPORE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    20. South Korea
    21. SOUTH KOREA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SOUTH KOREA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)SOUTH KOREA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    22. Taiwan
    23. TAIWAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)TAIWAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)TAIWAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    24. Thailand
    25. THAILAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)THAILAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)THAILAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    26. Vietnam
    27. VIETNAM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)VIETNAM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)VIETNAM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  11. Europe, Middle East & Africa Alpha Glucosidase Inhibitors Market
    1. Introduction
    2. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    3. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Denmark
    5. DENMARK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)DENMARK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)DENMARK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    6. Egypt
    7. EGYPT ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)EGYPT ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)EGYPT ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    8. Finland
    9. FINLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)FINLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)FINLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    10. France
    11. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    12. Germany
    13. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    14. Israel
    15. ISRAEL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)ISRAEL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)ISRAEL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    16. Italy
    17. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    18. Netherlands
    19. NETHERLANDS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)NETHERLANDS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)NETHERLANDS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    20. Nigeria
    21. NIGERIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)NIGERIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)NIGERIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    22. Norway
    23. NORWAY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)NORWAY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)NORWAY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    24. Poland
    25. POLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)POLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)POLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    26. Qatar
    27. QATAR ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)QATAR ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)QATAR ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    28. Russia
    29. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    30. Saudi Arabia
    31. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    32. South Africa
    33. SOUTH AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SOUTH AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)SOUTH AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    34. Spain
    35. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    36. Sweden
    37. SWEDEN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SWEDEN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)SWEDEN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    38. Switzerland
    39. SWITZERLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SWITZERLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)SWITZERLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    40. Turkey
    41. TURKEY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)TURKEY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)TURKEY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    42. United Arab Emirates
    43. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
    44. United Kingdom
    45. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  12. Competitive Landscape
    1. FPNV Positioning MatrixALPHA GLUCOSIDASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023ALPHA GLUCOSIDASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
    2. Market Share Analysis, By Key PlayerALPHA GLUCOSIDASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023ALPHA GLUCOSIDASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
    3. Competitive Scenario Analysis, By Key Player
  13. Competitive Portfolio
    1. Key Company Profiles
      1. Alkem Laboratories Ltd.
      2. Avecia Healthcare
      3. Bal Pharma Ltd.
      4. Bayer AG
      5. Biocon
      6. BioVision Inc. by Abcam US Group Holdings Inc.
      7. Cipla Ltd.
      8. Elder Pharmaceuticals Ltd.
      9. Empros Pharma AB
      10. Glenmark Pharmaceuticals Ltd.
      11. Lunan Pharmaceuticals Group
      12. Manus Aktteva Biopharma LLP
      13. Merck KGaA
      14. Micro Labs Ltd.
      15. Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd.
      16. Novo Nordisk A/S
      17. Samex Overseas
      18. Sanofi S.A.
      19. Shenzhen Haorui Pharmatech Co., Ltd.
      20. Straight Healthcare
      21. Strides Arcolab Limited
      22. Sun Pharmaceutical Industries Ltd.
      23. Takeda Pharmaceutical Co. Ltd.
      24. Torrent Pharmaceuticals Ltd.
      25. Wockhardt Ltd.
    2. Key Product Portfolio
  1. Alkem Laboratories Ltd.
  2. Avecia Healthcare
  3. Bal Pharma Ltd.
  4. Bayer AG
  5. Biocon
  6. BioVision Inc. by Abcam US Group Holdings Inc.
  7. Cipla Ltd.
  8. Elder Pharmaceuticals Ltd.
  9. Empros Pharma AB
  10. Glenmark Pharmaceuticals Ltd.
  11. Lunan Pharmaceuticals Group
  12. Manus Aktteva Biopharma LLP
  13. Merck KGaA
  14. Micro Labs Ltd.
  15. Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd.
  16. Novo Nordisk A/S
  17. Samex Overseas
  18. Sanofi S.A.
  19. Shenzhen Haorui Pharmatech Co., Ltd.
  20. Straight Healthcare
  21. Strides Arcolab Limited
  22. Sun Pharmaceutical Industries Ltd.
  23. Takeda Pharmaceutical Co. Ltd.
  24. Torrent Pharmaceuticals Ltd.
  25. Wockhardt Ltd.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Alpha Glucosidase Inhibitors Market
The Global Alpha Glucosidase Inhibitors Market size was estimated at USD 616.76 million in 2023 and expected to reach USD 703.76 million in 2024.
The Global Alpha Glucosidase Inhibitors Market to grow USD 1,591.49 million by 2030, at a CAGR of 14.50%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.